Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasiglucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Zealand Pharma

    • Most Recent Events

    • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 20 Mar 2018 According to a Zealand Pharma media release, the full results will be published at an appropriate scientific conference.
    • 20 Mar 2018 According to a Zealand Pharma media release, the first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary and key secondary objectives.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top